Vera Therapeutics Sees Unusually High Options Volume (NASDAQ:VERA)

31 Dec 2025, 13:45 by Teresa Graham · The Cerbat Gem

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) saw some unusual options trading on Wednesday. Investors acquired 7,008 call options on the company. This represents an increase of approximately 1,626% compared to the typical daily volume of 406 call options.

Insiders Place Their Bets

In other news, SVP Joseph R. Young sold 15,000 shares of Vera Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the sale, the senior vice president directly owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. The trade was a 23.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Patrick G. Enright acquired 5,882 shares of the stock in a transaction dated Thursday, December 11th. The stock was acquired at an average cost of $42.50 per share, with a total value of $249,985.00. Following the purchase, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 16.30% of the stock is owned by corporate insiders.

Institutional Trading of Vera Therapeutics

A number of large investors have recently modified their holdings of the stock. Hudson Bay Capital Management LP raised its holdings in shares of Vera Therapeutics by 47.4% during the 3rd quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock valued at $12,804,000 after buying an additional 141,615 shares during the period. Armistice Capital LLC increased its stake in shares of Vera Therapeutics by 294.1% in the third quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after acquiring an additional 400,000 shares during the last quarter. Verition Fund Management LLC bought a new position in shares of Vera Therapeutics in the 3rd quarter valued at approximately $1,188,000. Qube Research & Technologies Ltd increased its position in Vera Therapeutics by 47.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 461,410 shares of the company’s stock worth $13,409,000 after buying an additional 149,468 shares during the period. Finally, Prelude Capital Management LLC lifted its position in Vera Therapeutics by 81.8% in the third quarter. Prelude Capital Management LLC now owns 46,551 shares of the company’s stock worth $1,353,000 after purchasing an additional 20,951 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. Evercore ISI lifted their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Wedbush boosted their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a report on Friday, November 28th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $74.83.

Read Our Latest Analysis on Vera Therapeutics

Vera Therapeutics Stock Performance

VERA stock traded down $0.56 during trading hours on Wednesday, reaching $50.61. The stock had a trading volume of 440,101 shares, compared to its average volume of 1,422,306. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. Vera Therapeutics has a fifty-two week low of $18.53 and a fifty-two week high of $56.05. The stock has a market capitalization of $3.24 billion, a PE ratio of -12.69 and a beta of 1.21. The stock has a 50-day simple moving average of $37.11 and a 200 day simple moving average of $28.72.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the prior year, the company posted ($0.85) earnings per share. Analysts predict that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.